ERBB2 and breast carcinoma: In addition, another trial of metastatic HER2-positive breast cancer confirmed a greater benefit for T-DM1 in contrast to physicians’ choice (typically trastuzumab-based regimes) in patients with tumors with high HER2 expression [49].